Crucially, higher plasma CTGF levels were associated with shorter progression-free survival in ccRCC patients receiving AATs.<h4>Conclusion</h4>CTGF is a key mediator of resistance to AATs in ccRCC, by promoting tumor progression and remodeling the tumor microenvironment. The gene discussed is CCN2; the disease is nonpapillary renal cell carcinoma.